Clover Health Posts First-Ever GAAP Net Income in Q1 2026, Membership Soars 51%

What happened

Clover Health reported Q1 2026 GAAP net income of $27 million, a $29 million improvement year-over-year, marking its first profitable quarter. Total revenue surged 62% to $749 million, driven by a 51% jump in Medicare Advantage membership to 155,773. Consolidated gross profit rose 47% to $160 million, and Adjusted EBITDA hit $40 million, up 56%. Management maintained its full-year 2026 guidance for GAAP net income between $0 and $20 million, implying potential losses in subsequent quarters despite the strong start. The results validate the company's trajectory toward full-year profitability, but investors should monitor the sustainability of medical cost ratios and cash flow, as the benefits expense ratio remains a key risk.

Implication

The Q1 2026 GAAP net income of $27 million significantly exceeds the full-year guidance midpoint, indicating that Clover is ahead of schedule on profitability. However, management’s full-year guidance of $0–20 million GAAP net income implies that management expects losses in the remaining quarters, likely due to new member mix and seasonal utilization. The 51% membership growth is impressive, but rapid expansion typically pressures medical cost ratios initially, as noted in the DeepValue report. Adjusted EBITDA of $40 million provides a cushion, but stock-based compensation remains a drag on GAAP earnings, and cash flow from operations needs to turn positive to reduce dilution risk. Overall, the quarter is a positive catalyst that increases the probability of the base case ($2.40) and reduces the bear case probability, but full-year delivery remains unproven.

Thesis delta

The Q1 2026 results shift the thesis from 'potential turn' to 'confirmed early profitability,' but the full-year guidance tempers exuberance. The DeepValue report's base case assumed gradual improvement; the strong Q1 accelerates the timeline but also raises the bar for the rest of the year. If the benefits expense ratio does not deteriorate in Q2 and Q3, the stock could move toward the bull case of $3.20; otherwise, the current rally may fade.